Status:
COMPLETED
Intrathecal Analgesia Effects on Cancer Patients Discomfort Symptoms
Lead Sponsor:
University Hospital, Montpellier
Collaborating Sponsors:
Institut du Cancer de Montpellier - Val d'Aurelle
Centre Hospitalier Universitaire de Nīmes
Conditions:
Refractory Cancer Pain
Intrathecal Analgesia
Eligibility:
All Genders
18+ years
Brief Summary
Intrathecal analgesia is used in refractory cancer pain because of drug sides effects or intractable pain. The aim of this approach is to improve pain management, and also to improve patient comfort. ...
Detailed Description
Descriptive multicenter study including patients with refractory cancer pain (unmanageable drug sides effects or intractable pain) who will receive intrathecal analgesia Patient discomfort symptoms wi...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- patients aged 18 and older
- obligation of affiliation or beneficiary of a social security scheme
- patients with cancer and refractory localized cancer pain because of drug side effects or intractable pain
- localized pain in topography accessible to intrathecal analgesia (legs, abdomen and pelvis, pancoast-tobias symdrom)
- patient's informed consent for the study
- patient able to complete the evaluation questionnaires
- estimed vital prognosis more than three month
- patient with all conditions for intrathecal anagelsia
- Exclusion criteria:
- patient with intracranial hypertension
- refusal of patient to be included in the study
- refusal of patient to receive intrathecal analgesia
- patient with many refractory pain localizations not accessible to intrathecal analgesia
Exclusion
Key Trial Info
Start Date :
November 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04491123
Start Date
November 1 2018
End Date
June 30 2020
Last Update
July 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295